aibio
Distress ·
Skinvisible delays annual report for year ended December 31, 2024
The company said it could not compile all the information for its financial statements in time. It expects to file within the fifteen-day grace period.
SKVI Skinvisible, Inc.
Skinvisible (SKVI) news
Latest Skinvisible news
We have not published a story on Skinvisible yet. When there is news, it will appear here.
What Skinvisible does
Skinvisible, Inc. is a pharmaceutical research and development company that has developed and patented Invisicare, a polymer delivery system for topical skin products. The company says it has formulated over forty topical skin products, which it out-licenses globally to established manufacturers and marketers. It targets an estimated $80 billion global skincare and dermatology market and a $30 billion global over-the-counter market. Invisicare is designed to bind active ingredients to the skin for extended periods and to deliver them in a controlled release. Skinvisible generates revenue through licensing for an upfront fee and ongoing royalties, through co-development of early formulations for pharmaceutical clients, and through life cycle management that reformulates off-patent products with new Invisicare patents. Its licensee Quoin Pharmaceuticals, Inc. holds rights to certain patents for QRX003, a topical product being developed for Netherton Syndrome. The agreement calls for a $5 million milestone to Skinvisible upon the first FDA or European Union approval for one licensed product, and a single digit royalty on net sales.
| Product or program | What it is | Stage |
|---|---|---|
| Invisicare | Patented polymer delivery system for topical skin care products | patented |
| QRX003 | Topical product licensed to Quoin for Netherton Syndrome | in clinical trials (Quoin) |
Skinvisible annual financials
Questions about Skinvisible
What is the ticker symbol of Skinvisible?
Skinvisible, Inc. trades under the ticker SKVI on OTC.
Where is Skinvisible listed?
Skinvisible, Inc. is listed on OTC.
What is the SEC CIK of Skinvisible?
The SEC Central Index Key (CIK) for Skinvisible, Inc. is 1085277. Its filings are on SEC EDGAR.
How many shares does Skinvisible have outstanding?
5,403,843 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Which country or territory is Skinvisible listed under?
Our directory records Skinvisible, Inc. under United States.
What does Skinvisible do?
Our directory classifies Skinvisible, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Skinvisible?
The ISIN recorded for Skinvisible, Inc. is US8307032032.
Does aibio.space cover Skinvisible?
aibio.space lists Skinvisible, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Skinvisible incorporated?
SEC records list its state or country of incorporation as NV.
What does Skinvisible develop?
Skinvisible, Inc. is a pharmaceutical research and development company that has developed and patented Invisicare, a polymer delivery system for topical skin products. The company says it has formulated over forty topical skin products, which it out-licenses globally to established manufacturers and marketers.
What is Invisicare from Skinvisible?
Invisicare: Patented polymer delivery system for topical skin care products Stage: patented.
What is QRX003 from Skinvisible?
QRX003: Topical product licensed to Quoin for Netherton Syndrome Stage: in clinical trials (Quoin).
What was Skinvisible's revenue last year?
$20,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Skinvisible profitable?
Skinvisible, Inc. reported a net loss of $1.1 million for the fiscal year ended Dec 31, 2025, and used $38,410 of cash in operations, per its annual report to the SEC.
How much cash does Skinvisible have?
$3,959 in cash at Jun 30, 2026, per its 10-Q.
Investor discussion: Skinvisible
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Stock chart
SEC filings and registration
- SEC name
- Skinvisible, Inc.
- CIK
- 1085277
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- SKVI (OTC)
- State or country of incorporation
- NV
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 6320 S SANDHILL ROAD, LAS VEGAS, NV, 89120
- Phone
- 702-433-7154
- Shares outstanding
- 5,403,843 as of 2026-08-13 (10-Q filed 2026-08-13)
- Former names
- SKINVISIBLE INC
Recent filings
Listing details
- Company
- Skinvisible, Inc.
- Ticker
- SKVI
- Listing
- OTC
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US8307032032
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction